Things (like AML salvage) go better with VEN(etoclax).
作者信息
Winer Eric S, Stone Richard M
机构信息
Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA.
出版信息
Blood Adv. 2025 Jan 28;9(2):425-426. doi: 10.1182/bloodadvances.2024014778.
Abstract
摘要
相似文献
1
Things (like AML salvage) go better with VEN(etoclax).使用维奈克拉（VEN[etoclax]）治疗时，（如急性髓系白血病挽救治疗等）情况会更好。
Blood Adv. 2025 Jan 28;9(2):425-426. doi: 10.1182/bloodadvances.2024014778.
2
A retrospective comparison of salvage intensive chemotherapy venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML).复发/难治性急性髓系白血病（AML）患者挽救性强化化疗联合维奈克拉方案的回顾性比较
Ther Adv Hematol. 2022 Mar 23;13:20406207221081637. doi: 10.1177/20406207221081637. eCollection 2022.
3
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.基于维奈托克的挽救性治疗作为移植的桥梁，对于复发/难治性急性髓系白血病患者是可行且有效的。
Blood Adv. 2025 Jan 28;9(2):375-385. doi: 10.1182/bloodadvances.2024013086.
4
Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia.维奈托克添加到CLAG方案中可能会改善复发/难治性急性髓系白血病患者的预后。
Ther Adv Hematol. 2025 Feb 10;16:20406207251319603. doi: 10.1177/20406207251319603. eCollection 2025.
5
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.地西他滨联合维奈托克与强化化疗治疗复发或难治性急性髓系白血病的 10 天疗程：一项倾向评分匹配分析。
Cancer. 2021 Nov 15;127(22):4213-4220. doi: 10.1002/cncr.33814. Epub 2021 Aug 3.
6
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.维奈克拉治疗新诊断、复发或难治性急性髓系白血病患者的临床经验。
J Cancer Res Clin Oncol. 2022 Nov;148(11):3191-3202. doi: 10.1007/s00432-022-03930-5. Epub 2022 Jan 31.
7
Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.阿扎胞苷-维奈克拉与阿扎胞苷挽救治疗用于原发性诱导失败或首次复发的急性髓系白血病患者。
Eur J Haematol. 2024 Apr;112(4):530-537. doi: 10.1111/ejh.14140. Epub 2023 Nov 29.
8
[Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation].维奈托克治疗25例异基因造血干细胞移植后复发血液系统恶性肿瘤患者的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2022 Jul 14;43(7):542-549. doi: 10.3760/cma.j.issn.0253-2727.2022.07.003.
9
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.吉特替尼联合或不联合维奈托克治疗复发/难治性 FLT3 突变型急性髓系白血病。
Br J Haematol. 2024 Sep;205(3):932-941. doi: 10.1111/bjh.19548. Epub 2024 May 23.
10
Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML.新型 FLT3 和 MERTK 双重抑制剂 MRX-2843 与 venetoclax 联合应用对 FLT3-ITD AML 具有有前景的抗白血病活性。
Leuk Res. 2024 Sep;144:107547. doi: 10.1016/j.leukres.2024.107547. Epub 2024 Jun 24.
本文引用的文献
1
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.基于维奈托克的挽救性治疗作为移植的桥梁，对于复发/难治性急性髓系白血病患者是可行且有效的。
Blood Adv. 2025 Jan 28;9(2):375-385. doi: 10.1182/bloodadvances.2024013086.
2
Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.与其他疗法相比，接受阿扎胞苷和维奈克拉治疗的难治性或复发性急性髓系白血病成人患者的结局：一项多中心回顾性研究。
Leuk Lymphoma. 2024 Dec;65(13):1974-1982. doi: 10.1080/10428194.2024.2390574. Epub 2024 Aug 11.
3
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.复发或反应不佳的急性髓系白血病患者的缓解诱导与立即进行异基因造血干细胞移植（ASAP）：一项随机、开放标签、3期、非劣效性试验。
Lancet Haematol. 2024 May;11(5):e324-e335. doi: 10.1016/S2352-3026(24)00065-6. Epub 2024 Apr 4.
4
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.维奈托克联合 FLAG-IDA 诱导和巩固治疗新诊断的急性髓系白血病。
Am J Hematol. 2022 Aug;97(8):1035-1043. doi: 10.1002/ajh.26601. Epub 2022 May 30.
5
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.CPX-351 与 venetoclax 和阿扎胞苷在急性髓系白血病中的真实世界疗效。
Blood Adv. 2022 Jul 12;6(13):3997-4005. doi: 10.1182/bloodadvances.2022007265.
6
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.维奈托克联合阿扎胞苷与诱导化疗治疗初诊急性髓系白血病患者的比较。
Blood Adv. 2021 Dec 28;5(24):5565-5573. doi: 10.1182/bloodadvances.2021005538.
7
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Venetoclax 治疗复发/难治性 AML 的反应和生存的临床和分子预测因子。
Blood Adv. 2021 Mar 9;5(5):1552-1564. doi: 10.1182/bloodadvances.2020003734.
8
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.维奈托克联合地西他滨与强化化疗治疗急性髓系白血病的疗效比较：基于治疗相关死亡率风险的倾向评分匹配分析。
Am J Hematol. 2021 Mar 1;96(3):282-291. doi: 10.1002/ajh.26061. Epub 2020 Dec 24.
9
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
10
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.维奈托克联合 LDAC 方案用于不适合强化化疗的新诊断 AML：一项 3 期随机安慰剂对照试验。
Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856.
Zotero 插件